AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Boston Beer Company Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Gevo, Inc. has filed a Form 144 indicating a proposed sale of 43,964 common shares through broker Stifel Nicolaus on or about 01 Aug 2025. The shares carry an estimated aggregate market value of $49,472, implying a price near $1.13 and amounting to just 0.018 % of the company’s 239.6 million shares outstanding, suggesting minimal dilution or control impact. The seller attests that no material non-public adverse information exists.

The filer acquired 78,237 restricted stock units on 26 Jul 2025 and, in the past three months, sold 73,934 shares on 30 May 2025 for $94,783. While the notice may hint at continued insider monetisation, the absolute size and relative stake are immaterial to the capital structure and market liquidity.

Gevo, Inc. ha presentato un Modulo 144 che indica una vendita proposta di 43.964 azioni ordinarie tramite il broker Stifel Nicolaus intorno al 01 agosto 2025. Le azioni hanno un valore di mercato aggregato stimato di 49.472 $, con un prezzo vicino a 1,13 $, corrispondente a solo lo 0,018% delle 239,6 milioni di azioni in circolazione, suggerendo un impatto minimo su diluizione o controllo. Il venditore dichiara che non esistono informazioni riservate negative rilevanti.

Il dichiarante ha acquisito 78.237 unità azionarie vincolate il 26 luglio 2025 e, negli ultimi tre mesi, ha venduto 73.934 azioni il 30 maggio 2025 per 94.783 $. Sebbene l’avviso possa suggerire una continua monetizzazione interna, la dimensione assoluta e la quota relativa sono irrilevanti per la struttura del capitale e la liquidità di mercato.

Gevo, Inc. ha presentado un Formulario 144 indicando una venta propuesta de 43,964 acciones ordinarias a través del corredor Stifel Nicolaus alrededor del 01 de agosto de 2025. Las acciones tienen un valor de mercado agregado estimado de $49,472, con un precio cercano a $1.13, representando solo el 0.018% de las 239.6 millones de acciones en circulación, lo que sugiere un impacto mínimo en la dilución o control. El vendedor afirma que no existe información confidencial adversa material.

El declarante adquirió 78,237 unidades restringidas de acciones el 26 de julio de 2025 y, en los últimos tres meses, vendió 73,934 acciones el 30 de mayo de 2025 por $94,783. Aunque el aviso puede indicar una monetización continua por parte de los internos, el tamaño absoluto y la participación relativa son insignificantes para la estructura de capital y la liquidez del mercado.

Gevo, Inc.ëŠ� 2025ë…� 8ì›� 1ì¼ê²½ 브로ì»� Stifel Nicolausë¥� 통해 43,964 보통ì£�ë¥� 매ë„í•� ì˜ˆì •ìž„ì„ ì•Œë¦¬ëŠ� Form 144ë¥� 제출했습니다. 해당 주ì‹ì� ì˜ˆìƒ ì´� 시장 가치는 49,472 달러ë¡�, 주당 ì•� 1.13 달러ì—� 해당하며, 회사ì� ì´� 발행 ì£¼ì‹ 2ì–� 3,960ë§� ì£� ì¤� 0.018%ì—� 불과í•� í¬ì„ì´ë‚˜ 지배력ì—� 미치ëŠ� ì˜í–¥ì€ 미미í•� 것으ë¡� 보입니다. 매ë„ìžëŠ” 중요í•� 비공ê°� ë¶€ì •ì  ì •ë³´ê°€ ì—†ìŒì� 확ì¸í–ˆìŠµë‹ˆë‹¤.

ì‹ ê³ ìžëŠ” 2025ë…� 7ì›� 26ì¼ì— 78,237 제한 ì£¼ì‹ ë‹¨ìœ„ë¥� ì·¨ë“했으ë©�, ì§€ë‚� 3개월 ë™ì•ˆ 2025ë…� 5ì›� 30ì¼ì— 73,934 ì£�ë¥� 94,783 달러ì—� 매ë„했습니다. ì� 통지ëŠ� ë‚´ë¶€ìž� ìžì‚° 현금화가 계ì†ë� ìˆ� 있ìŒì� 시사하지ë§�, 절대 규모와 ìƒëŒ€ ì§€ë¶„ì€ ìžë³¸ 구조와 시장 유ë™ì„±ì— í� ì˜í–¥ì� 미치지 않습니다.

Gevo, Inc. a déposé un formulaire 144 indiquant une vente proposée de 43 964 actions ordinaires via le courtier Stifel Nicolaus aux alentours du 1er août 2025. Les actions ont une valeur de marché agrégée estimée à 49 472 $, ce qui implique un prix proche de 1,13 $ et représente seulement 0,018 % des 239,6 millions d’actions en circulation, suggérant un impact minimal sur la dilution ou le contrôle. Le vendeur atteste qu’aucune information défavorable non publique importante n’existe.

Le déclarant a acquis 78 237 unités d’actions restreintes le 26 juillet 2025 et, au cours des trois derniers mois, a vendu 73 934 actions le 30 mai 2025 pour 94 783 $. Bien que l’avis puisse laisser entendre une monétisation continue par les initiés, la taille absolue et la participation relative sont insignifiantes pour la structure du capital et la liquidité du marché.

Gevo, Inc. hat ein Formular 144 eingereicht, das einen geplanten Verkauf von 43.964 Stammaktien über den Broker Stifel Nicolaus um den 01. August 2025 anzeigt. Die Aktien haben einen geschätzten Gesamtmarktwert von 49.472 $, was auf einen Kurs von etwa 1,13 $ hindeutet und nur 0,018 % der 239,6 Millionen ausstehenden Aktien des Unternehmens entspricht, was auf eine minimale Verwässerung oder Einflussnahme auf die Kontrolle schließen lässt. Der Verkäufer versichert, dass keine wesentlichen nicht öffentlichen negativen Informationen vorliegen.

Der Melder erwarb am 26. Juli 2025 78.237 eingeschränkte Aktieneinheiten und verkaufte in den letzten drei Monaten am 30. Mai 2025 73.934 Aktien ´Úü°ù 94.783 $. Obwohl die Mitteilung auf eine fortgesetzte Monetarisierung durch Insider hindeuten könnte, sind die absolute Größe und der relative Anteil ´Úü°ù die Kapitalstruktur und die Marktliquidität unerheblich.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small Form 144 for 44k GEVO shares; dollar value trivial, unlikely to move stock, but signals incremental insider selling trend.

The proposed 43,964-share disposition is worth under $50k and equals less than two-hundredths of one percent of shares outstanding. Such volume should not create meaningful supply pressure nor affect voting power. However, it extends a pattern: the same insider sold ~74k shares two months earlier. Persistent insider selling—even at modest scale—can influence sentiment in a cash-burning, early-stage biofuels company like Gevo. From a governance lens, the certification that no undisclosed negative information exists reduces information-asymmetry concerns. Overall, the filing is not materially impactful but merits monitoring if cumulative insider dispositions accelerate.

Gevo, Inc. ha presentato un Modulo 144 che indica una vendita proposta di 43.964 azioni ordinarie tramite il broker Stifel Nicolaus intorno al 01 agosto 2025. Le azioni hanno un valore di mercato aggregato stimato di 49.472 $, con un prezzo vicino a 1,13 $, corrispondente a solo lo 0,018% delle 239,6 milioni di azioni in circolazione, suggerendo un impatto minimo su diluizione o controllo. Il venditore dichiara che non esistono informazioni riservate negative rilevanti.

Il dichiarante ha acquisito 78.237 unità azionarie vincolate il 26 luglio 2025 e, negli ultimi tre mesi, ha venduto 73.934 azioni il 30 maggio 2025 per 94.783 $. Sebbene l’avviso possa suggerire una continua monetizzazione interna, la dimensione assoluta e la quota relativa sono irrilevanti per la struttura del capitale e la liquidità di mercato.

Gevo, Inc. ha presentado un Formulario 144 indicando una venta propuesta de 43,964 acciones ordinarias a través del corredor Stifel Nicolaus alrededor del 01 de agosto de 2025. Las acciones tienen un valor de mercado agregado estimado de $49,472, con un precio cercano a $1.13, representando solo el 0.018% de las 239.6 millones de acciones en circulación, lo que sugiere un impacto mínimo en la dilución o control. El vendedor afirma que no existe información confidencial adversa material.

El declarante adquirió 78,237 unidades restringidas de acciones el 26 de julio de 2025 y, en los últimos tres meses, vendió 73,934 acciones el 30 de mayo de 2025 por $94,783. Aunque el aviso puede indicar una monetización continua por parte de los internos, el tamaño absoluto y la participación relativa son insignificantes para la estructura de capital y la liquidez del mercado.

Gevo, Inc.ëŠ� 2025ë…� 8ì›� 1ì¼ê²½ 브로ì»� Stifel Nicolausë¥� 통해 43,964 보통ì£�ë¥� 매ë„í•� ì˜ˆì •ìž„ì„ ì•Œë¦¬ëŠ� Form 144ë¥� 제출했습니다. 해당 주ì‹ì� ì˜ˆìƒ ì´� 시장 가치는 49,472 달러ë¡�, 주당 ì•� 1.13 달러ì—� 해당하며, 회사ì� ì´� 발행 ì£¼ì‹ 2ì–� 3,960ë§� ì£� ì¤� 0.018%ì—� 불과í•� í¬ì„ì´ë‚˜ 지배력ì—� 미치ëŠ� ì˜í–¥ì€ 미미í•� 것으ë¡� 보입니다. 매ë„ìžëŠ” 중요í•� 비공ê°� ë¶€ì •ì  ì •ë³´ê°€ ì—†ìŒì� 확ì¸í–ˆìŠµë‹ˆë‹¤.

ì‹ ê³ ìžëŠ” 2025ë…� 7ì›� 26ì¼ì— 78,237 제한 ì£¼ì‹ ë‹¨ìœ„ë¥� ì·¨ë“했으ë©�, ì§€ë‚� 3개월 ë™ì•ˆ 2025ë…� 5ì›� 30ì¼ì— 73,934 ì£�ë¥� 94,783 달러ì—� 매ë„했습니다. ì� 통지ëŠ� ë‚´ë¶€ìž� ìžì‚° 현금화가 계ì†ë� ìˆ� 있ìŒì� 시사하지ë§�, 절대 규모와 ìƒëŒ€ ì§€ë¶„ì€ ìžë³¸ 구조와 시장 유ë™ì„±ì— í� ì˜í–¥ì� 미치지 않습니다.

Gevo, Inc. a déposé un formulaire 144 indiquant une vente proposée de 43 964 actions ordinaires via le courtier Stifel Nicolaus aux alentours du 1er août 2025. Les actions ont une valeur de marché agrégée estimée à 49 472 $, ce qui implique un prix proche de 1,13 $ et représente seulement 0,018 % des 239,6 millions d’actions en circulation, suggérant un impact minimal sur la dilution ou le contrôle. Le vendeur atteste qu’aucune information défavorable non publique importante n’existe.

Le déclarant a acquis 78 237 unités d’actions restreintes le 26 juillet 2025 et, au cours des trois derniers mois, a vendu 73 934 actions le 30 mai 2025 pour 94 783 $. Bien que l’avis puisse laisser entendre une monétisation continue par les initiés, la taille absolue et la participation relative sont insignifiantes pour la structure du capital et la liquidité du marché.

Gevo, Inc. hat ein Formular 144 eingereicht, das einen geplanten Verkauf von 43.964 Stammaktien über den Broker Stifel Nicolaus um den 01. August 2025 anzeigt. Die Aktien haben einen geschätzten Gesamtmarktwert von 49.472 $, was auf einen Kurs von etwa 1,13 $ hindeutet und nur 0,018 % der 239,6 Millionen ausstehenden Aktien des Unternehmens entspricht, was auf eine minimale Verwässerung oder Einflussnahme auf die Kontrolle schließen lässt. Der Verkäufer versichert, dass keine wesentlichen nicht öffentlichen negativen Informationen vorliegen.

Der Melder erwarb am 26. Juli 2025 78.237 eingeschränkte Aktieneinheiten und verkaufte in den letzten drei Monaten am 30. Mai 2025 73.934 Aktien ´Úü°ù 94.783 $. Obwohl die Mitteilung auf eine fortgesetzte Monetarisierung durch Insider hindeuten könnte, sind die absolute Größe und der relative Anteil ´Úü°ù die Kapitalstruktur und die Marktliquidität unerheblich.

false000094987000009498702025-08-012025-08-01

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 01, 2025

 

 

The Boston Beer Company, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Massachusetts

001-14092

04-3284048

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One Design Center Place

Suite 850

 

Boston, Massachusetts

 

02210

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 368-5000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A Common Stock. $0.01 par value

 

SAM

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of President and Chief Executive Officer

The Boston Beer Company, Inc. (the “Company”) announced today that Michael Spillane has decided to step down from his position of President and Chief Executive Officer, effective August 15, 2025, and as noted in more detail below he will remain in an advisory role with the Company through March 31, 2026. Mr. Spillane has led the Company as CEO since March 2024 and has served on the Board since 2016. He will remain as a non-independent member of the Board of Directors through his current term that expires at the Company’s 2026 Annual Meeting. Whether Mr. Spillane will stand for reelection to the Board at the Company’s 2026 Annual Meeting will be determined at a later date. Should he be nominated and elected at the 2026 Annual Meeting, Mr. Spillane would be eligible for the same levels of compensation as other non-employee Directors.

Mr. Spillane informed the Board that his decision to step down was for personal reasons and was not due to any disagreements with the Company on any matter relating to the Company’s operations, policies, or practices.

He will be succeeded as President and CEO by C. James Koch, the Company’s Founder and Chairman. As the Company’s President and CEO, Mr. Koch will also serve as President of each of the Company’s subsidiaries. Mr. Koch will continue to serve as Chairman of the Board and will stand for reelection at the Company’s 2026 Annual Meeting. Mr. Koch formerly served as the Company’s President and CEO from its founding in 1984 through January 2001. He will re-assume the position of President and CEO on August 16, 2025. Mr. Koch’s compensation as President and CEO will remain as previously reported and will not be adjusted as a result of assuming the new role.

Outgoing CEO Agreement

Effective on August 1, 2025, Mr. Spillane entered into an agreement (the “Transition Agreement”) with the Company that details the financial and other principal matters that will govern Mr. Spillane’s continuing relationship with the Company through March 31, 2026. The provisions of the Transition Agreement were approved by the Board of Directors and the Compensation Committee of the Board of Directors on August 1, 2025. A copy of the agreement is attached hereto as Exhibit 10.1.

Mr. Spillane will remain as a salaried employee of the Company through November 15, 2025, and will then be engaged by the Company in an advisory role, as a consultant, during the period from November 16, 2025 through March 31, 2026. His compensation through November 15, 2025 will be at the annual rate of $905,000, which is his current annual salary. His compensation as an advisor will be $10,000 per quarter, with his fourth quarter 2025 advisory compensation pro-rated from November 16, 2025 to December 31, 2025.

At its meeting on February 5, 2025 and as reported in the Current Report on Form 8-K filed by the Company on February 11, 2025, the Compensation Committee set Mr. Spillane’s bonus target for 120% of salary. The Transition Agreement effectively limits his covered salary to the salary earned by him while President and CEO through August 15, 2025. The amount of his 2025 bonus will be dependent upon the Company’s results pursuant to its bonus scale and will be determined by the Compensation Committee as part of its standard procedures in February 2026.

As a consequence of his continuing advisory relationship with the Company, prior year equity grants will continue to vest subject to and in accordance with their respective terms through March of 2026. In the Transition Agreement, the Company has agreed not to terminate Mr. Spillane’s relationship with the Company prior to March 31, 2026, except in the event of the occurrence of certain events described in the Transition Agreement.

Mr. Spillane is not eligible for further equity grants.

Mr. Spillane will continue to participate through November 15, 2025 in all of the various fringe benefits and perquisites that he currently enjoys, on the same basis as such benefirts and perquisites are currently provided, subject only to such changes as may be adopted by the Company and apply to all executive officers of the Company. His rights to elect continued health care coverage under COBRA take effect as of November 16, 2025. Provided he remains eligible for and timely elects to continue receiving group medical insurance pursuant to COBRA, the Company will continue to pay, or reimburse him for during the period November 15, 2025 through August 16, 2026, or until he has secured other employment or is no longer


eligible for coverage under COBRA, whichever occurs first, the portion of the premium for the cost of health coverage under COBRA in excess of the active-employee portion of such premium paid by him as of November 16, 2025, payable on a monthly basis during such period.

Mr. Spillane’s responsibilities through March 31, 2026, after he steps down as President and CEO, are to advise Mr. Koch on such matters as they may mutually agree.

Pursuant to the Transition Agreement, Mr. Spillane has also confirmed his obligations under the Executive Employee Restrictive Covenant Agreement (the “Covenants”) that was executed by him when he accepted the role of President and CEO. The Covenants are more fully described in the Current Report on Form 8-K filed by the Company on February 27, 2025.

The Transition Agreement also contains mutual releases and non-disparagement provisions.

Press Release

The Company issued a press release announcing Mr. Spillane’s resignation and Mr. Koch’s appointment as President and CEO on August 1, 2025, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are filed as part of this report:

Exhibit No.

Description

 

 

10.1

Transition Agreement governing Mr. Spillane’s ongoing relationship with the Company, dated August 1, 2025

99.1

 

Press Release announcing Mr. Spillane’s resignation and Mr. Koch’s appointment as President and CEO, dated August 1, 2025

104

 

Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

The Boston Beer Company, Inc.

 

 

 

 

Date:

August 1, 2025

By:

/s/ C. James Koch

 

 

 

Name: C. James Koch
Title: Founder & Chairman

 


FAQ

How many GEVO shares are covered by the new Form 144 filing?

The notice covers 43,964 common shares of Gevo, Inc.

When is the anticipated sale date for the GEVO shares?

The filing lists an approximate sale date of 01 Aug 2025.

What percentage of Gevo’s outstanding shares does the planned sale represent?

The 43,964 shares equal roughly 0.018 % of the 239.6 million shares outstanding.

Which broker will execute the proposed GEVO share sale?

Stifel Nicolaus & Company, Inc., located at 501 N Broadway, St. Louis, MO 63102.

Were there recent insider sales preceding this filing?

Yes. The filer sold 73,934 shares on 30 May 2025 for $94,783.
Boston Beer

NYSE:SAM

SAM Rankings

SAM Latest News

SAM Latest SEC Filings

SAM Stock Data

2.31B
7.89M
8.4%
82.04%
6.1%
Beverages - Brewers
Malt Beverages
United States
BOSTON